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RNA sequencing revealed novel actors of the
acquisition of drug resistance in Candida albicans
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Abstract
Background: Drug susceptible clinical isolates of Candida albicans frequently become highly tolerant to drugs
during chemotherapy, with dreadful consequences to patient health. We used RNA sequencing (RNA-seq) to
analyze the transcriptomes of a CDR (Candida Drug Resistance) strain and its isogenic drug sensitive counterpart.
Results: RNA-seq unveiled differential expression of 228 genes including a) genes previously identified as involved
in CDR, b) genes not previously associated to the CDR phenotype, and c) novel transcripts whose function as a
gene is uncharacterized. In particular, we show for the first time that CDR acquisition is correlated with an
overexpression of the transcription factor encoding gene CZF1. CZF1 null mutants were susceptible to many drugs,
independently of known multidrug resistance mechanisms. We show that CZF1 acts as a repressor of β-glucan
synthesis, thus negatively regulating cell wall integrity. Finally, our RNA-seq data allowed us to identify a new
transcribed region, upstream of the TAC1 gene, which encodes the major CDR transcriptional regulator.
Conclusion: Our results open new perspectives of the role of Czf1 and of our understanding of the transcriptional
and post-transcriptional mechanisms that lead to the acquisition of drug resistance in C. albicans, with potential for
future improvements of therapeutic strategies.
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Background
The yeast Candida albicans is the major cause of oppor-
tunistic fungal infections in humans. In case of systemic
infections, the mortality rate can reach 50% [1]. Azoles,
which target the fungal P450 cytochrome 14alpha-
lanosterol demethylase encoded by the ERG11 gene, are
the most commonly used antifungal molecules for candi-
dosis treatment [2]. Unfortunately azoles only have a fun-
gistatic effect and therefore have allowed the emergence
of multidrug resistance strains in patients [3]. There are
two main groups of mutations which cause azole resist-
ance in Candida albicans. The first group directly targets
ERG11, either in cis by creating ERG11 alleles which en-
code a protein variant insensitive to azoles [4], or in trans
by increasing the expression of ERG11 through gain of
function mutations in the UPC2 gene, which encode a
transcription factor regulating ERG11 [5]. The second type
acts by increasing the expression of membrane transpor-
ters which export the drugs and therefore decrease their
intracellular concentration [5]. Two types of drug resist-
ance, called MDR and CDR respectively, are distinguished,
depending on the type of transporters which is involved.
In most of the clinical isolates studied so far, the cells
present either a drug resistance of the MDR or the CDR
type [5,6]. Only in rare occurrences, the two kind of resist-
ance can be observed in the same cells [6-8]. The MDR
resistant cells overexpress the Mdr1 permease encoding
gene, which is under the control of the Mrr1 and Cap1
transcription factors [9]. MDR1 is homologous to the Sac-
charomyces cerevisiae FLR1 transporter, which is involved
in the detoxification of several drugs, including the anti-
fungal benomyl [8,10,11]. The CDR resistant strains over-
express two ABC transporters encoding genes, CDR1 and
CDR2, which are homologous to the pleiotropic drug re-
sistance transporter Pdr5 from S. cerevisiae [12,13]. These
transporters are major determinants of the resistance to
fluconazole, the most widely used azole. Their expression
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is controlled mainly by the Tac1 transcription factor [14].
Most of the CDR resistant strains present a loss of hetero-
zygocity and/or aneuploidy at the TAC1 locus, combined
to gain of function mutations of TAC1 [15,16]. Microarray
and proteomic analyses identified about 30 genes which
are co-overexpressed with CDR1 and CDR2 in all CDR
clinical isolates examined [17,18]. Chromatine immuno-
precipitation and tac1Δ strain analyses identified the
TAC1 regulon, which is composed of about ten genes
mostly involved in membrane properties, including CDR1,
CDR2, the phospholipid transferase gene PDR16, the pu-
tative flippase gene RTA3 or the putative sphingosine kin-
ase gene LCB4 [18,19].
The recently developed RNA sequencing (RNA seq)
technology is revolutionizing our ability to analyse
eukaryotic transcriptomes [20-22] and has given a chance
to unravel the actual complexity of the CDR phenotype
better. RNA seq has been proven to be more sensitive
than microarrays [21]. RNA seq also results in more ac-
curate measurements of gene expression changes [23].
Moreover, relative to standard microarray approaches,
RNA seq and tiling arrays provide crude measurement
and identification of transcripts, without any a priori on
which region of the genome is transcribed [24,25]. Hence,
two recent RNA seq and one tiling array analyses of the
Candida albicans transcriptome identified more than
1000 new transcripts, many of which are expressed in a
condition-specific way [25-27]. Most of these transcripts
do not have a coding potential and may be long non cod-
ing regulatory RNAs.
In this study, we have used RNA seq to analyse the
transcriptomes of a CDR strain and its isogenic drug
susceptible counterpart. In addition to the genes previ-
ously shown to be associated with CDR, we could iden-
tify about 50 genes which were overexpressed in the
CDR strain. In particular, we show that the transcription
factor encoding gene CZF1, which is involved in hyphal
transition and white/opaque switching, is induced to-
gether with CDR1 and CDR2 in Gu5. Czf1 is likely to
play an important role in CDR acquisition since its over-
expression is a general feature of all the CDR strains that
we have tested, but was not found in MDR strains.
Moreover, its deletion caused susceptibility to several
unrelated drugs. Additionally, the inactivation of CZF1
increased the resistance of the cells to cell wall pertur-
bating agents, through the overexpression of beta glucan
synthesis genes. We propose that Czf1 has a positive role
on drug resistance and a negative role on cell wall integ-
rity. Finally, we characterized a new transcribed region,
previously undetected, just upstream of the TAC1 gene,
which strongly suggests that TAC1 is subjected to com-
plex post-transcriptional regulations, yet to be character-
ized. Taken together, our results open several new ways
to our understanding of drug resistance acquisition in
Candida albicans and may provide new targets for anti-
fungal therapies.
Results
Transcriptional landscape of Gu4 and Gu5 strains
In order to conduct a comparative analysis of the tran-
scriptomes of CDR versus drug susceptible C. albicans
cells, we performed high-throughput sequencing of
cDNA made from poly(A) RNAs obtained from the Gu4
and Gu5 strains. Gu4 is a fluconazole susceptible clinical
isolate obtained from an early infection episode. Gu5 is
the corresponding fluconazole resistant clinical isolate
obtained from later episode in the same patient treated
with fluconazole. Gu4 and Gu5 are therefore supposed
to be isogenic and mainly differ by their resistance to
fluconazole. Gu5 has been characterised as a CDR strain,
showing overexpression of CDR1 and CDR2, as com-
pared with Gu4 [28]. For each strain, two biologically in-
dependent samples of RNAs were analysed by RNA seq.
We obtained 27 763 991 unique mappable reads for Gu4
(96% of total reads) and 20 570 932 mappable reads for
Gu5 (97% of total reads). As noticed in previous RNA
seq studies, the background was very low, with no or
few reads mapped in intergenic regions. The correlation
coefficient between the biological replicates was very
high (0.991 for Gu5 and 0.999 for Gu4). We could detect
expression for 5727 (92%) of the 6177 ORFs annotated
in the CGD. The 450 ORFs which were undetected in
our experiments are mostly dubious ORFs or gene with-
out clear function (71%). We arbitrarily grouped the
expressed ORFs in five categories: very high expression
(more than 1000 reads/nucleotides), high expression (be-
tween 100 and 1000 reads/nucleotides), medium expres-
sion (between 10 and 100 reads/nucleotides), low
expression (below 10 reads/nucleotides) and very low
expression (below 3 reads/nucleotides). These categories
contained 3%, 20%, 57%, 12% and 8% of the genes, re-
spectively. As described previously, the “very high ex-
pression” category was enriched in genes encoding
ribosomal proteins, glycolytic enzymes, translation regu-
lators, histones and components of respiratory com-
plexes. The “high expression” category was enriched in
genes encoding enzymes involved in various metabo-
lisms. The “medium” and “low” expression categories
did not show any significant functional enrichment.
We used our data to define the boundaries of each
transcript, as described previously [25]. We compared
the 5’ and 3’UTR predictions that we obtained with the
annotation set up by a previous RNA seq analysis of the
Candida albicans reference strain SC5314 [25]. We
found no significant difference in the two annotations
for more than 75% of the genes, indicating that our data
is reliable and that there is no global change in 5’ and
3’UTR length between those strains. Still, we had some
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significant discrepancies with the annotation from Bruno
et al. for about thirty genes, which showed much longer
5’ or 3’ UTR according to our data (Additional file 1:
Table S1). This is for instance the case of TAC1, ADAEC
and CZF1 (Figure 1). These genes did not show any par-
ticular functional enrichment. Noteworthy, we did not
detect significant differences in the size of transcripts be-
tween the Gu4 and Gu5 strains, with the notable and
Figure 1 Expression profiles obtained for TAC1, ADAEC and CZF1. The density of reads along the genome has been visualized using
Integrative Genome Viewer (IGV) and the CGD annotation. The signal is in reads/nucleotides. The coordinates and the transcript annotations
previously available [25] are indicated below each IGV capture. TAC1 and ADAEC present extension in 5’ in our data as compared with previous
annotations. In the case of TAC1, this extension was detected only in the Gu5 strain.
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sole exception of TAC1 which presented an extension in
5’ which was apparently specific for the azole resistant
strain (Figure 1).
Finally, we used our data to detect new transcripts. To
do so, the reads from the Gu4 and Gu5 strains were
summed and used to identify regions of the genome
with a minimum coverage of at least 3 reads/nucleotides
(with at least one read in three independent samples) for
a stretch of at least 50 nucleotides. With these criteria,
we identified 1130 new transcription units, 800 of which
partially or totally overlapped new transcribed regions
recently identified by RNA seq [25,26] or tiling arrays
[27] (Additional file 1: Table S2). We named these new
transcripts NGuTs for “New Gu strains Transcripts”.
The median size of NGuTs was 425 nucleotides. The
majority of these NGuTs did not contain any obvious
ORF and are therefore likely to be non-coding RNAs.
Transcripts differentially expressed in the drug resistant
and the drug susceptible strains
The identification of genes differentially expressed in
Gu4 and Gu5 was performed combining two different
statistical methods (see methods section) and using the
gene annotations from the CGD, the new transcribed
regions defined by previous studies [25-27] and the new
transcribed regions defined in this study (see above). We
found 130 genes significantly overexpressed in Gu5 and
92 genes which were underexpressed in this strain com-
pared to Gu4 (a full list and description of these genes
can be found in Additional file 1: Table S3).
Comparison with previous microarray experiments
We first compared our results with the one obtained in
a previous study, which used microarrays to analyse the
transcriptomes of 4 different CDR isolates [18]. Among
the 130 genes induced in Gu5, 74 (56.5%) were previ-
ously shown to be overexpressed in one or several of
these CDR clinical isolates (Additional file 1: Table S3).
Among these 74 genes, 53 (72%) were found overex-
pressed in at least 3 of the 4 CDR strains, suggesting
that most of the genes identified in our RNA seq ana-
lyses are general features of the CDR isolates. These
genes include the CDR1 and CDR2 ABC transporter en-
coding genes, together with the TAC1 gene encoding
their transcriptional regulator. Remarkably, all the previ-
ously identified targets of Tac1p are found in our list, in-
cluding PDR16, RTA3 and LCB4.
Of the 92 genes underexpressed in Gu5, 42 (46%) were
previously shown to be repressed in CDR isolates. This
includes genes involved in iron and metal homeostasis
(FTR1, SIT1, FET34 for instance) and amino acid metab-
olism (MET3, OPT7, GAP4, SAM4 for instance).
ORFs not previously associated with CDR
We identified 53 ORFs which were overexpressed in
Gu5 and were not previously associated with CDR
phenotype. About half of them (45%) are uncharacter-
ized and little information is available on their function.
Among the characterized genes (Figure 2 and Add-
itional file 1: Table S3), some of them were known as
playing important roles in morphogenesis, hyphal
growth and white/opaque switch. This is the case of the
transcription factors Czf1 and Sfl2, the kinase Sch9, the
membrane sensor Gpr1 and its target Ece1, the signal
transducer Srr1, the white specific gene of unknown
function ADAEC and the cytoplasmic protein Wh11.
Some other induced genes are involved in cell wall
maintenance and cell adhesion, like the mannosyl-
transferase Mnn4 or the adhesion protein Als1. Finally,
two transporters encoding genes belong to this list:
Yor1, which is homologous to an oligomycin resistance
gene of S. cerevisiae and Hgt10, which encodes a gly-
cerol permease involved in osmotic stress response. Re-
markably, four of the CDR induced genes (CZF1, TAC1,
ADAEC and orf19.6713) present the particularity to have
Figure 2 New genes induced or repressed in the CDR isolate.
This figure represents a subset of the genes (and associated
functions) which were induced or repressed in the Gu5 strain
compared with Gu4 and which were not previously associated to
CDR acquisition. The complete list of genes up- or down-regulated
in Gu5 is available in Additional file 1: Table S3.
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a long transcribed region upstream of the start codon
according to our RNA seq data, which could be inter-
preted either as long 5’ UTR or as new non coding tran-
scripts (see Figure 1 and chapter below).
Fifty genes were shown for the first time to be down-
regulated in Gu5. Of these, 24 (49%) are uncharacter-
ized. Among the verified ORFs (Figure 2 and Additional
file 1: Table S3), we could find the gene encoding the
ABC transporter Cdr4, which is homologous to Cdr1
and Cdr2, and RTA4, which is homologous to the Tac1
target, RTA3. We also found in this group additional
genes involved in copper and iron homeostasis (HEM13,
CRP1 and SMF3) and genes encoding extracellular pro-
teins (PLB1, ALS2, MAL2). Two genes encoding poten-
tial steroid targets, EBP1 and CBP1, were also
underexpressed in Gu5, which is interesting considering
the previously established link between steroid exposure
and CDR response [29].
To support these results, we performed semi-quantitative
RT-PCR analyses for 6 repressed and 8 induced genes,
using actin as a reference and CDR1 as a positive control
(Figure 3). These experiments confirmed the RNA seq
results, except for EBP1 and orf19.3769, for which no differ-
ence of expression was detected by this method.
New transcripts differentially expressed in Gu5 and Gu4
strains
Among the new transcripts identified in this study, 5
were overexpressed and 8 underexpressed in Gu5 com-
pared with Gu4. Four of the five induced transcripts
were located immediately in 5’ of an induced ORF.
Transcript NGuT-chr4-123 (previously identified as
NOVEL-Ca21chr4-073 in [25]) was in 5’ of CZF1
(Figure 1), NGuT-chr5-037 was in 5’ of TAC1 (Figure 1),
NGUT-chr2-038 was in 5’ of ADAEC (Figure 1) and
NGuT-chr3-128 (previously identified as TF3W223 in
[27]), was close to orf19.6713. The fifth transcript,
NGuT-chr3-105 (NOVEL-Ca21chr3-056), is located just
upstream of the AAF1 gene, which encodes an adhesin
and which is not induced in the Gu5 strain.
All the new transcripts which were repressed in Gu5 are
located at more than 1 kb from the adjacent ORFs. NGUT-
chrR-157 (NOVEL-Ca21chrR-103) and 160 (TFRW269)
belong to the same cluster of non coding RNAs. NGUT-
chr4-069 (NOVEL-Ca21chr4-040) is located in a zone rich
in tRNA genes. NGUT-chrR-041 (NOVEL-Ca21chrR-026)
is close to a long terminal repeat.
Semi-quantitative RT-PCR analyses for 4 repressed
and 3 induced NGuTs, using actin as a reference con-
firmed the RNA seq results, except for NGuT-chr3-105
and NGUT-chrR-157 (Figure 3).
New roles of the Czf1p transcription factor in multidrug
resistance and cell wall maintenance
CZF1 deletion alters drug resistance
To go further in our investigation of the roles of new
genes involved in the acquisition of CDR, we selected
three of the induced genes, MNN4 (for mannosylpho-
sphorylation), CZF1 (C. albicans Zinc Finger protein),
and ALS1 (Agglutinin Like Sequence), and performed
drug sensitivity profiling with the corresponding null
mutants (Figure 4A). Serial dilutions of cells were grown
on agar plates and minimum inhibitory concentration
(MIC) was determined by broth microdilution assay with
different concentrations of FLC, terbinafin (TER), aniso-
mycin (ANS), amphotericin B (AMB), and ketoconazole
(KTC) (Figure 4B). The homozygous mutants for MNN4
and ALS1 did not exhibit any significant differences with
their respective wild type strains. However, czf1 null mu-
tant displayed enhanced susceptibility to FLC, TER and
Figure 3 Confirmation of RNA seq results by semi-quantitative RT-PCR. Final point semi-quantitative RT-PCR was used to validate some of
the genes found to be differentially expressed by RNA seq. CDR1 was used as a positive control of a gene induced in the Gu5 strain. ACT1 was
used as a reference gene equally expressed in Gu5 and Gu4. The genes for which the PCR results did not confirm the RNA seq results are marked
by a cross on the right of the gel picture.
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ANS in comparison to its wild type strain (Figure 4A).
MIC80 of the czf1 null strain was calculated as 0.12, 1
and 3.12 μg/ml for FLC, TER, and ANS, respectively,
which was ~ 3 fold less than its isogenic wild type
(Figure 4B). Notably, the strain heterozygous for the de-
letion of CZF1 had wild type levels of drug resistance
(data not shown). czf1 nulls did not show any differential
susceptibility to AMB or KTC (Figure 4).
CZF1 deletion does not impair the expression of standard
MDR and CDR actors
To understand the molecular basis of the drug sensitivity
described above, we measured, in the wild type and in
strains mutated for one or both copies of CZF1, the ex-
pression levels of major actors of multidrug resistance
pathways (CDR1, MDR1, UPC2, PDR16, HSP104) or of
genes changing expression in Gu5 in our experiments
(CDR4, YOR1, WH11). Final point semi-quantitative RT-
PCR did not show any difference in the level of these
genes in the wild type and in strains mutated for one or
both copies of CZF1, indicating that Czf1 does not act
on the steady state expression of MDR and CDR actors
in a laboratory strain (Figure 5A).
CZF1 negatively controls beta-glucan synthesis and
resistance to cell wall perturbation agents
The sensitivity of the czf1 null mutant to various drugs
prompted us to test the phenotype of this mutant in pres-
ence of drugs targeting the calcineurin pathway or cell
wall integrity. Calcineurin has been shown to play mul-
tiple roles in stress responses including resistance to FLC
and to membrane perturbation [30,31]. It has also been
shown to influence the dimorphic switch, a process which
is controlled by Czf1 [31]. We tested growth of wild type,
czf1Δ/czf1Δ or czf1Δ/CZF1 strains in presence of the
membrane perturbation agent SDS and the specific calci-
neurin inhibitor FK506. We observed that the double mu-
tant was more sensitive to these drugs than the single
mutant and the wild type strain (Figure 5C). We tested
the expression of several direct or indirect actors of the
calcineurin pathway (CMP1, CNB1, CRZ1, HSP90 and
HOG1). We did not detect any effect of the partial or total
inactivation of CZF1 on the expression of these genes
(Figure 5B). Reciprocally, we tested the expression of
CZF1 in various strains mutated for one or several actors
of the calcineurin pathway. Again, we did not see any
effects of the inactivation of the calcineurin pathway on
the steady-state expression of CZF1 (data not shown).
In C. albicans, the cell wall plays important roles in viru-
lence, defense against host and resistance to some drugs
[32]. Surprisingly, we observed that the czf1Δ/czf1Δ strain
was more resistant than the wild type to congo red (a cell
wall perturbation agent) (Figure 5C). The heterozygous mu-
tant exhibited an intermediate phenotype (haploinsuffi-
ciency), suggesting a dosage effect for the role of CZF1 in
cell wall maintenance. Congo red is considered to act on
the cell wall glucan structure. Therefore, we measured the
expression of the three beta 1,3-glucan synthase encoding
genes (GSC1, GSL1 and GSL2) in presence and absence of
CZF1 (Figure 5B). We observed no or few differences in
GSC1 and GSL2 expression. In contrast, we observed a
clear overexpression of GSL1 in the strains deleted for one
or two copies of CZF1, compared to the wild type. This re-
sult suggests that Czf1 negatively controls the expression of
this gene and that the resistance to congo red that we
observed in the czf1 mutants could be linked to the partial
deregulation of beta-glucan synthesis. Interestingly, a defect
in beta-glucan activity has been shown to cause sensitivity
to many different drugs, including azoles [33]. However, the
expression of GSL1, GSC1 and GSL2, tested by RNA-seq
and semi-quantitative RT-PCR, was unchanged in the Gu5
strain as compared with Gu4 (data not shown).
CZF1 overexpression is commonly associated with CDR
acquisition
To check whether an upregulation of CZF1 is a general
phenomenon among drug resistant clinical isolates, we
examined the expression of CZF1 in six azole sensitive
Figure 4 Phenotypic profiling of some strains mutated for
genes induced in Gu5. (A). Serial dilution assays showing drugs
susceptibilities of strains deleted for genes found to be induced in
Gu5 and of their isogenic wild type parents. (B). MIC80 calculated for
each drug and each strain. FLC, terbinamycin (TER), anisomycin
(ANS), amphotericin B (AMB), and ketoconazole (KTC).
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(AS) and azole resistant (AR) matched pairs (Figure 6).
The first group of AS/AR isolates includes strains
(DSY347/DSY289; DSY544/DSY775 and Gu4/Gu5)
in which the AR isolate is characterized by the
overexpression of CDR1 and CDR2 (CDR group). The sec-
ond group included strains (F2/F5; G2/G5 and DSY290/
DSY292) where AR isolates showed an overexpression of
MDR1 (MDR group). Our quantitative RT-PCR data
Figure 5 Effects of CZF1 deletion on genes involved in CDR, calcineurin or beta-glucan biosynthesis pathways. The expression of several
genes involved either in CDR (A) or calcineurin and beta glucan biosynthesis patways (B) was measured in czf1Δ/czf1Δ, czf1Δ/CZF1 and wild type
strains by final point semi-quantitative RT-PCR. GSL1 is the only gene that seemed to be affected by the inactivation of CZF1 in these
experiments. ACT1 was used as a reference gene. (C) growth assays testing the sensitivity of the strains mentioned above to drugs associated to
SDS, FK520 and congo red.
Figure 6 CZF1 induction is commonly associated with CDR acquisition. The expression of CZF1 was measured by final point semi-
quantitative RT-PCR in different pairs of drug sensitive/resistant strains presenting either a drug resistance of the CDR or of the MDR kind. On the
right panel, the expression of CZF1 was measured in a series of isolates coming from the same patient at different step of fluconazole resistance
acquisition [34]. Seventeen isolates were available from the original publication, four of them (numbers 1, 8, 9 and 17) were tested here. The
MIC50 of each isolate for fluconazole is indicated. ACT1 was used as a reference gene.
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revealed that CZF1 was upregulated in two AR isolates of
the CDR group and one of the MDR group (DSY290/
DSY292; DSY347/DSY289; Gu4/Gu5) (Figure 6, upper
left). In contrast, the levels of CZF1 remained unchanged
in the other pairs of isolates (Figure 6, bottom left). We
next analyzed the expression of CZF1 in a series of clinical
isolates acquired from a single HIV-infected patient over
the period of two years where the levels of FLC resistance
of the strain increased over 200-fold [34] (Figure 6, right
panel). We observed a gradual overexpression of CZF1,
which followed the increase in FLC resistance of those iso-
lates (Figure 6, right panel).
Taken together these results strongly suggest that the
overexpression of CZF1 is generally correlated to the ac-
quisition of the CDR phenotype, with the notable excep-
tion of the DSY544/DSY775 pair.
Discussion
In this work, we have used RNA-seq to analyze the tran-
scriptome changes associated with CDR acquisition in a
pair of clinical isolates in the human pathogen C. albicans.
Our aim was to obtain an accuracy, sensitivity and com-
pletion unreached by previous microarray analyses of the
same strains. Based on previous RNA-seq studies, we
expected a better detection of mRNAs and of their expres-
sion changes, the identification of unannotated transcripts
possibly up or down regulated in the CDR strain, and the
detection of changes in the 5’ and 3’ UTR lengths com-
pared with available annotations. Indeed, our data pointed
out about one hundred genes, which were either induced
or repressed in the Gu5 strain compared with Gu4, and
which were not associated to CDR acquisition by previous
studies. Although we identified more than one thousand
new transcripts (some previously annotated by RNA seq
or tiling arrays, some completely new), very few of them
changed expression in the CDR strain. Four of these new
transcripts were found to be induced in Gu5, but their
position just upstream of annotated genes, which are simi-
larly induced in Gu5, raises doubts on their actual exist-
ence as independent transcripts, or as long, previously
undetected, 5’ UTR of the downstream gene.
The analyses of this large amount of data led to two
important conclusions, which open new perspectives for
our understanding of multidrug resistance in this patho-
genic yeast. First, we revised the annotation of the TAC1
genomic region, identifying a new transcribed region in
5’ of the TAC1 mRNA. Second, we suggested new roles
for the Czf1 transcription factor in CDR acquisition and
cell wall maintenance.
A new transcribed region upstream of TAC1 and its
potential impact on TAC1 expression regulation
RNA seq and tiling arrays experiments have allowed the
systematic annotation of transcript boundaries in three
yeast species: S. cerevisiae, C. albicans and C. parapsilo-
sis [21,25,27,35]. In all three species, the 5’ and 3’UTR
have been shown to be generally short, with an average
size ranging between 50 and 80 nucleotides. However, in
all these species, many exceptions have been described.
In C. albicans, about 100 genes have 5’ UTR longer than
500 bp [27]. Interestingly, this group is enriched in genes
encoding transcriptional regulators and genes involved
in filamentation. These include the CZF1 transcription
factor encoding gene, which was induced in our experi-
ments and which has a 5’UTR of about 2 kb ([27,36];
this study). This observation is also true in mammals in
which many genes with long 5’UTR encode regulators
and proto-oncogenes [37]. Long 5’UTR usually have im-
portant roles in the post-transcriptional and translational
regulation of gene expression. In the yeast Saccharo-
myces cerevisiae, the expression of several transcription
factors, including Gcn4 (amino acid starvation), Yap1
(oxidative stress response) and Yap2 (cadmium re-
sponse), is regulated by the presence of short upstream
ORFs (uORFs) in their long 5’UTR region, which exert
negative or positive actions on the translation of the
main ORF or on mRNA stability, depending on the cel-
lular context [38]. Recent studies have identified about
250 genes containing potential uORFs in this species
[21].
As mentioned in the introduction, TAC1 encodes the
major transcriptional regulator of CDR genes. Its own
mRNA expression is co-induced with those of its main
targets, CDR1 and CDR2, possibly due to an autoregula-
tory loop [18,29]. In previous transcript annotations,
TAC1 mRNA was described as having a 5’UTR of about
300 nt [25,27]. Our RNA seq data detected a transcribed
region up to 1 kb upstream of the TAC1 start codon,
which was apparently specific of the Gu5 strain
(Figure 1). This could be interpreted as a new transcript
expressed only in the CDR strain, as an alternative tran-
scription start site (TSS) specific for Gu5 (alternative
TSS had been described in C. albicans, for instance in
the case of the EFG1 transcription factor encoding gene
[39]) or as the normal TSS of TAC1 which could not be
detected in drug sensitive strains because expression of
TAC1 in those strains and RNA-seq coverage in previous
experiments and in this study were too low. 5’RACE and
northern blot experiments could resolve if it is an alter-
native TSS or a new transcript. However, the strong cor-
relation between the expression of the two regions
(Figures 1 and 3) suggests that TAC1 mRNA presents, at
least in the Gu5 strain, an unusually long 5’UTR, which
was previously not detected. Considering the important
roles of long 5’UTR in translation regulation, this opens
exciting new perspectives to the post-transcriptional
regulation of TAC1 expression, which was poorly investi-
gated until now. Especially, we observed in this 5’UTR
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the presence of one large (about 50 codons) uORF in
the same orientation and phase than the TAC1 ORF
(Figure 7), which suggests the existence of regulatory
mechanisms similar to the ones described for GCN4,
YAP1 or YAP2 in S. cerevisiae. The analysis of ribosome
occupancy at TAC1 mRNA in CDR matched pairs, ei-
ther measured by global ribosome profiling or by poly-
somes gradients, will give information on this potential
regulation. Moreover, a long 5’UTR would have import-
ant implications on the way we consider the transcrip-
tional regulation of TAC1. Indeed, yeast enhancers are
usually located close upstream to the TSS. Since 5’UTR
regions are also limited in size, people tended to look for
DNA consensus motifs within 800 bp upstream of the
start codon of the genes. The fact that the actual TSS of
TAC1 would be located about 0.8 kb upstream of all pre-
vious estimations also change the potential position of
its promoter region. For instance, it was shown that
Tac1 binds its own promoter, which led to the hypoth-
esis that it is regulated through a positive auto-
regulatory loop [18]. However, this hypothesis was chal-
lenged by the fact that the two potential Tac1 binding
motifs (DRE) in this region were located more than 1 kb
upstream of TAC1 ATG. In the annotation proposed in
Figure 7, these DRE would be located very close to the
TSS, which strongly supports their functional role in the
activation of TAC1 expression.
New roles for Czf1 in CDR acquisition and cell wall
maintenance
Czf1 is a zinc finger transcription factor mostly known
for its role in the epigenetic white/opaque switch, which
controls cell and colony morphogenesis and properties
[40]. Czf1 acts synergistically to Wor1 and Wor2 tran-
scription factors, and antagonistically to Efg1, to pro-
mote the opaque state. Czf1 also has a role in hyphal
growth, (also called filamentation). Czf1 mutants filament
normally under standard filamentation induction condi-
tions, but they are defective in hyphal development in an-
aerobic conditions [41]. This phenotype is dependent on
the composition of the media, for instance in terms of car-
bon source. The positive role of Czf1 on hypoxic filamen-
tation is under the negative control of the TOR pathway
and more specifically, of the Sch9 kinase [42]. As for the
white/opaque switch, Efg1 plays an important and com-
plex role in filamentation. In aerobic conditions, it is a
positive regulator of hyphal development, whereas in hyp-
oxia, it counteracts the positive action of Czf1 on this
process [43]. Direct cross-talks exist between Efg1 and
Czf1: Efg1 binds to the promoter of CZF1 and repress its
expression, while Czf1 has a similar effect on the EFG1
promoter [36,44]. More recently, Czf1 has been shown to
be required for wild type adherence to silicone devices
[45]. Despite these roles in morphogenesis, the list of Czf1
targets has not been established to date. A partial tran-
scriptome analysis of the czf1 mutant, conducted on 250
genes using the Nanochip technology, detected very few
expression changes in this mutant [45].
Our data strongly suggest that Czf1 plays a role in the
acquisition of multidrug resistance of the CDR type.
First, CZF1 is overexpressed in all CDR mutants that we
tested. Noteworthy, some other actors of white/opaque
switch and hyphal growth were also overexpressed in
the Gu5 strain, including SCH9, ADAEC, WH11 or
SFL2. Second, the czf1 null mutant is sensitive to many
unrelated drugs, including azoles and molecules target-
ing the calcineurin pathway. Remarkably, CZF1 does not
seem to be involved in drug resistance phenotypes of the
MDR kind, since its expression was unchanged in MDR
mutant strains. The drug sensitivity associated with the
inactivation of Czf1 does not seem to be due to standard
drug resistance pathways, since the level of expression of
the main actors of the CDR, MDR and calcineurin path-
ways were unchanged in this mutant. However, the fact
that Czf1 does not control the steady-state expression
levels of those genes does not mean that it is not
involved in their induction following drug exposure.
This hypothesis will be tested by inactivating CZF1 in
the Gu5 and Gu4 backgrounds and testing the effect of
this inactivation on drug resistance and gene expression.
Surprisingly, we observed that the czf1 mutant was re-
sistant to congo red, a cell wall perturbation agent which
targets beta-glucans, the most abundant component of
Candida albicans cell wall. This phenotype was haploin-
sufficient, since the heterozygous mutant exhibited an
intermediate resistance between the null mutant and the
Figure 7 New annotation of the 5’ region of TAC1. The positions of the start codon (ATG), the transcription start site, the potential uORF in
the 5’UTR (together with its sequence) and the two Tac1 binding sites (DRE) are indicated.
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wild type. Congo red is thought to target the glucan
architecture by directly interacting with glucan chains,
therefore inhibiting synthesis of glucan polymers [46].
We observed that the GSL1 gene encoding one of the
three beta 1,3 glucan synthase subunits, was strongly
overexpressed in the czf1 mutant. This suggests that
Czf1 has a negative effect on the expression of some of
the actors of the glucan synthesis pathway, which could
explain the congo red resistance observed in the null
mutant. Many functional connections have been estab-
lished between cell wall components and hyphal growth.
GSL1 itself has been shown to be down-regulated during
filamentation [47], a process that is positively regulated
by Czf1. Notably, Efg1 is also involved in cell wall archi-
tecture and efg1 mutants show a haploinsufficiency
phenotype [47,48]. The deletion of one or two copies of
EFG1 leads to a decrease in the expression of many
enzymes involved in cell wall biogenesis, including
beta1-3 glucan synthases. This causes important changes
in cell wall thickness and composition [48]. Again, Czf1
and Efg1 seem to antagonize each other in the regula-
tion of cell wall maintenance. The over-expression of
some cell wall protein encoding genes has been exten-
sively described as a compensatory mechanism in re-
sponse to impairments in cell wall biosynthesis or to cell
wall damages, both in S. cerevisiae and C. albicans (see
for instance [49-51]). This phenomenon is largely con-
trolled by the cell wall integrity (CWI) pathway [52] but
part of it is independent of CWI [53]. For instance, treat-
ment with caspofungin (which directly inhibits the activ-
ity of the essential beta-glucanase subunit encoded by
GSC1) triggers a compensatory process which leads to
the overexpression of GSL1, similarly to what was
observed in the czf1 null mutant [51]. We suggest that
Czf1 could play a role in this process.
Conclusions
In conclusion, our results led us to propose two new
roles for Czf1 in drug resistance and cell wall mainten-
ance (Figure 8). The connection between these two roles
is unclear. Several cell wall proteins are induced in CDR
strains (CRH11, ALS1, SCW11, PGA13, AGP2, IFF4,
RBT5, EXG2, ECM331, CSP37, etc.) ([18]; this study).
However, some CDR strains have cell wall defects, while
others (including Gu5) seem to have normal cell wall
architectures (Singh and Prasad, submitted). As men-
tioned above, Gsc1 (previously known as Fks1) is the
main target of antifungals of the echinocandin family
(which includes caspofungin) and mutations in GSC1
confer resistance to these drugs [54,55]. However, nei-
ther GSL1 nor GSC1 show any significant changes in the
CDR strains and the GSL1 overexpression in the czf1
null mutant does not explain the large spectrum of drug
sensitivity observed for this strain. The systematic
determination of the Czf1 targets by transcriptomic ana-
lyses of the czf1 mutant and chromatine immunoprecipi-
tation will certainly thrfow some light on its role in
these two processes.
Methods
Material
All the media components were obtained from HiMedia
(Mumbai, India). Amphotericin B (AMB), terbinafin,
anisomycin, ketoconazole, sodium dodecyl sulphate,
FK520, congo red were purchased from Sigma chemicals
Co. (St. Louis, MO). Ranbaxy India generously provided
FLC. Reverse transcriptase kit was purchased from fer-
mentas, India. Caspofungin was generously provided by
Dr. Neeraj Chauhan (Public Health Research Institute
and Department of Microbiology and Molecular Genet-
ics, New Jersey, USA). dATP, dGTP, dTTP and dCTP
were bought from Sigma chemicals Co. (St. Louis, MO).
Yeast strains and growth conditions
Gu4 and Gu5 strains were described elsewhere [28]. The
strains of Candida albicans mutated in various genes
(ALS1, MNN4, CZF1) that were used for phenotypic
tests, were obtained from Dr. Ibrahim, A.S. (David
Geffen School of Medicine at UCLA Los Angeles Bio-
medical Research Institute), Dr. Gow, N. (The university
of Aberdeen, Scotland) and Dr. Kumamoto, C.A. (Tufts
University, Boston, USA) respectively. The complete list
of strains can be found in Additional file 1: Table S4.
Cells were grown in YPD rich medium (2% glucose, 1%
bactopeptone, 1% yeast extract) at 30°C for 48 hrs.
Figure 8 New roles for Czf1. Czf1 had been shown to antagonize
the role of Efg1 in hypoxic filamentation and white/opaque
switching. In this study, we suggest new roles for Czf1 in MDR and
in cell wall architecture. In this last role, Czf1 would antagonize the
positive role of Efg1 on the expression of genes involved in cell wall
biosynthesis and maintenance, as for instance in the case of GSL1.
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RNA extraction
Twenty ml of exponentially growing (OD= 0.6-0.7) Gu4
or Gu5 cells were flash frozen in 30 ml of cold ethanol,
centrifuged for 5 minutes at 3000 g, washed with sterile
water and centrifuged again. The cell pellets were stored
at −80°C. RNA were extracted using the RNeasy kit
(Qiagen), with DNAse treatment. The RNA quality was
checked on a bioanalyzer Nanochip (Agilent).
RNA sequencing
cDNA libraries and sequencing
Strand non-specific cDNA libraries (mRNA-Seq 8-Sample
Prep Kit) were prepared according to manufacturer’s
instructions (Illumina). The validation of libraries was
made with Bioanalyser DNA 1000 chip (Agilent). All li-
braries were sequenced in single read mode, using a Gen-
ome Analyser instrument (Illumina).
Reads mapping and counting
Before read mapping, we trimmed polyN read tails,
removed reads with a length lower or equals to 11 bases
and discarded reads with quality mean lower or equals
to 12. We aligned from the 4 samples a total of
48334923 bp single end reads produced from the Illu-
mina GAII device using the SOAP2 software (version
2.20) [56] on the Candida albicans genome (assembly
21). The mapping tool was configured to return all
alignment hits by setting the seed length to 28 bp. In
addition we authorized with SOAP2 up to 5 mismatches
with 2 in the seed.
Before expression estimation, alignments from reads
that matches more than one time on the reference gen-
ome were removed. In addition, we searched for new
transcripts by combining the Gu4 and Gu5 reads and
identifying regions of the genome with a minimum
coverage of at least 3 reads/nucleotides (with at least
one read in three independent samples) for a stretch of
at least 100 nucleotides. To compute gene expression
abundance, we used Candida albicans GFF genome an-
notation from assembly 21 together with the annotation
file for new transcripts and we counted all overlapping
regions between alignments and listed exons. The
complete results have been deposited at the GEO data-
base (accession number: GSE38298).
Data mining
Functional analyses of the genome-wide data were con-
ducted using the CGD GO (gene ontology) term finder
[57], with default parameters.
Differential analyses
Genes differentially expressed between Gu5 and Gu4
strains were identified applying two different methodolo-
gies available in the R programming language, i.e. DESeq
[58] and edgeR [59,60]. Default parameters were used
and genes with p-value lower than 0.01 with the two
methods were finally selected for further analysis (Add-
itional file 1: Table S3).
Final point semi-quantitative RT-PCR analyses
RT-PCR was done using the RevertAidTM H Minus kit
(MBI, Fermentas). Briefly, 1 μg isolated RNA was primed
with oligo (dT)18 for cDNA synthesis at 42°C for
60 min. Reverse transcription reaction was terminated
by heating at 70°C for 5 min. The synthesized cDNA
product (2 μl) was directly used for PCR amplification
reaction (50 μl) using gene specific forward and reverse
primers. The amplified products were gel electrophor-
esed and quantitated by using Quantity One software by
Bio Rad gel documentation system. The RNA samples
used for these validation experiments were independent
from the samples used for RNA seq. The sequences of
the primers used for PCR reactions can be found in
Additional file 1: Table S5.
Phenotypic tests
Drug-susceptibility was tested by broth-microdilution
assay according to CLSI (Clinical and Laboratory Stan-
dards Institute) and serial dilution assay essentially as
described previously (CLSI, 2008). Following drugs
stocks (in parenthesis) and working concentration were
used 2.5 μg/ml of FLC (5 mg/ml), 4 μg/ml of TER
(4 mg/ml), 4 μg/ml of AMB (4 mg/ml), 150 μg/ml of
ANS (20 mg/ml), 0.5 μg/ml of KTC (1 mg/ml), 50 ng/ml
of CAS (1 mg/ml), 0.08% SDS, 200 μg/ml of CR (10 mg/
ml), and 200 μg/ml FK520 (20 mg/ml).
Additional file
Additional file 1: Table S1. Genes with enlarged 3' or 5' UTR
boundaries as compared with the annotation of Bruno et al. 2010. Table
S2. annotation and coordinates of new transcripts found based on our
RNA seq data. Overlap with previously annotated transcripts are indicated
(annotations taken from Candida Genome Database, Bruno et al., 2010;
Sellam et al., 2010 and Tuch et al., 2010). Table S3. CDR Induced genes.
Genes that were found significantly overexpressed in Gu5 by Deseq and
EdgeR. Log2(ratios) are indicated, together with CGD descriptions. The
CDR isolates column indicate the number of different isolates in which
the gene was previously found to be overexpressed, based on the
studies of Liu et al., 2007 and Znaidi et al., 2006. Table S4. List of the
strains used in the study. Table S5. Sequences of the primers used in the
study.
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